Nektar Therapeutics Raises $250 Million After Alopecia Drug Sends Stock Up 18%
NEW YORK, April 21 —
Nektar Therapeutics launched a $250 million common stock offering the same week its alopecia drug data sent shares up 18.3%.
- NKTR jumped 18.3% on positive alopecia trial results to $98.765 a share
- The $250mn equity raise is roughly 4.5x the company's $55mn in trailing twelve-month revenue
- Citi flagged a 30-day catalyst window; a securities class action deadline hits May 5
What Actually Happened
Nektar got good drug data and immediately sold stock into the rally. That's the biotech playbook, and Nektar ran it by the book. Positive alopecia trial results drove shares up 18.3%. Days later, the company filed a $250mn common stock offering to lock in the higher price.
The raise dwarfs current revenue. Nektar pulls in $55mn over the trailing twelve months and trades at a negative 8.8x forward P/E — Wall Street still expects losses. The $250mn buys time. Alopecia is a large addressable market with few approved treatments in certain segments. Nektar wants enough cash to fund later-stage trials without raising again at a lower stock price.
The Catch
Two problems. First, dilution. Selling $250mn in common stock against $55mn in revenue means a real hit to existing shareholders. The 18.3% gain shrinks once new shares hit the float. Biotech investors know this pattern: the rally that funds the raise is often the rally you should have sold into.
Second, a securities class action lawsuit with a May 5 deadline is hanging over the stock. Biotech lawsuits are common and often go nowhere. But the timing creates noise right when the company needs a clean setup for Citi's 30-day catalyst window. If detailed trial data lands during that window and impresses, the lawsuit fades to background. If the data disappoints, dilution plus litigation plus fading enthusiasm could compress the stock fast.
Bottom Line
This is a pipeline bet, not a fundamentals story. At negative forward earnings and $55mn in revenue, Nektar is priced entirely on what its alopecia program could become. The $250mn raise is sound treasury management — you sell stock when you can, not when you must. But anyone buying today is paying a price that already reflects the good news. The share count is about to go up.
The next two events set the direction: the offering's final pricing and the Phase trial data readout within Citi's catalyst window. They will determine whether the 18% move was the start of a run or the peak.
Want to see Nektar's full financial breakdown, valuation, and risk profile? Generate a free NKTR report on Basis Report.
Basis Report does not hold positions in securities discussed. This is not investment advice.